Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of VX-661 in Combination With Ivacaftor on Chest Imaging in Cystic Fibrosis
2019-002189-11Phase 2
- Sponsor
- Vertex Pharmaceuticals
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cystic fibrosis (CF) comparing Tezacaftor + ivacaftor with Placebo (2 arms). Primary endpoint: Change in CT imaging score from baseline at Week 72.
02
Drugs
tezacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2019-002189-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002189-11.